OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press14110.17650/1818-8346-2015-10-2-14-25HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯClinical and economic analysis of voriconazole using for treatment of invasive aspergillosis in Russian FederationКлинико-экономический анализ использования вориконазол а для лечения инвазивного аспергиллеза в Российской ФедерацииIgnatievaV. I.ИгнатьеваВ. И.
Russian Federation
ignateva@hta-rus.ruAvksentievaM. V.АвксентьеваМ. В.
Russian Federation
Russian Presidential Academy of National Economy and Public AdministrationРоссийская академия народного хозяйства и государственной службы при президенте РФ82, Bldg. 1 Prosp. Vernadskogo, Moscow, 119571, RussiaРоссия, 119571, Москва, проспект Вернадского, 82, стр. 182, Bldg. 1 Prosp. Vernadskogo, Moscow, 119571, Russia I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaРоссия, 119571, Москва, проспект Вернадского, 82, стр. 1 ГБОУ ВПО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава России8, Bldg. 2 Trubetskaya St., Moscow, 119991, RussiaРоссия, 119991, Москва, ул. Трубецкая, 8, стр. 20406201510214250406201504062015https://oncohematology.abvpress.ru/ongm/article/view/141

Introduction. Based on clinical studies data voriconazole is recommended as the drug of choice for treatment of invasive aspergillosis (IA) – a widespread infectious complications occurring in immunocompromised patients and is characterized by severe clinical course and high mortality.

The aim of this study was to assess the cost-effectiveness of voriconazole compared to other preparations recommended in the Russian practice for the treatment of IA in adult patients.

Materials and methods. The authors constructed a «decision tree» type of model, which compared the three treatment alternatives for the IA in adult patients, depending on the drug in first-line therapy: 1) voriconazole, 2), caspofungin, or 3) amphotericin B lipid complex (LC). Efficacy was assessed as the probability of patient survival within 14 weeks of starting treatment. We took into account the drugs cost and an increase in the hospitalization duration due to the development of serious adverse events. The model parameters were determined on the basis of the published results of clinical studies, the costs were calculated on the basis of medicines prices in the public procurement and the average bed-day cost in system of obligatory health insurance. Probabilistic sensitivity analysis was performed.

Results. It has been shown that the use of voriconazole for treatment of IA is the dominant strategy compared to the use of caspofungin and amphotericin B LC, providing cost reduction while achieving maximum effect. Probabilistic sensitivity analysis (1000 simulations) showed stability of the revealed pattern.

Conclusion. The use of voriconazole in the treatment of IA allows to save the greatest number of lives at minimal cost compared to other preparations recommended in the Russian practice.

invasive aspergillosispharmacoeconomicsmodelingcost-effectivenessvoriconazolecaspofunginamphotericin Bamphotericin B lipid complexcost-benefit analysisefficiency analysissensitivity analysisинвазивный аспергиллезфармакоэкономикамоделированиеэффективность затратвориконазолкаспофунгинамфотерицин Влипидный комплекс амфотерицина Ванализ затратанализ эффективностианализ чувствительности1. Dignani M. C. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep 2014;6:81.Dignani M. C. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Rep 2014;6:81.2. Cornet M., Fleury L., Maslo C. et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002;51(4):288–96.Cornet M., Fleury L., Maslo C. et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002;51(4):288–96.3. Wald A., Leisenring W., van Burik J. A., Bowden R. A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175(6):1459–66.Wald A., Leisenring W., van Burik J. A., Bowden R. A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175(6):1459–66.4. Herbrecht R., Denning D., Patterson T. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–15.Herbrecht R., Denning D., Patterson T. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–15.5. Walsh T. J., Anaissie E. J., Denning D. W. et al.; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327–60.Walsh T. J., Anaissie E. J., Denning D. W. et al.; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327–60.6. Herbrecht R., Flückiger U., Gachot B. et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer (Suppl) 2007;5(2):49–59.Herbrecht R., Flückiger U., Gachot B. et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer (Suppl) 2007;5(2):49–59.7. Maertens J., Marchetti O., Herbrecht R. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46:709–18.Maertens J., Marchetti O., Herbrecht R. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46:709–18.8. Mousset S., Buchheidt D., Heinz W. et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014;93:13–32.Mousset S., Buchheidt D., Heinz W. et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014;93:13–32.9. Протокол лечения и профилактики кандидоза и аспергиллеза у взрослых больных лейкозами, лимфомами и депрессиями кроветворения. В кн.: Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. 1056 с. [The protocol of treatment and prevention of candidiasis and aspergillosis in adult patients with leukemia, lymphoma and hematopoiesis depression. In: Program treatment of blood diseases: Diagnostic and treatment protocols for hematological diseases. V. G. Savchenko (ed.). M.: Praktika, 2012. 1056 p. (In Russ.)].Протокол лечения и профилактики кандидоза и аспергиллеза у взрослых больных лейкозами, лимфомами и депрессиями кроветворения. В кн.: Программное лечение заболеваний системы крови: Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В. Г. Савченко. М.: Практика, 2012. 1056 с. [The protocol of treatment and prevention of candidiasis and aspergillosis in adult patients with leukemia, lymphoma and hematopoiesis depression. In: Program treatment of blood diseases: Diagnostic and treatment protocols for hematological diseases. V. G. Savchenko (ed.). M.: Praktika, 2012. 1056 p. (In Russ.)].10. Колбин А. С., Королева О. А., Климко Н. Н. Оценка эффективности затрат применения вориконазола для лечения инвазивного аспергиллеза. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2009;3:46–55. [Kolbin A. S., Koroleva O. A., Klimko N. N. Evaluation of the costeffectiveness of voriconazole for treatment of invasive aspergillosis. Farmacoeconomicа. Sovremennaya armakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology 2009;3:46–55. (In Russ.)].Колбин А. С., Королева О. А., Климко Н. Н. Оценка эффективности затрат применения вориконазола для лечения инвазивного аспергиллеза. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2009;3:46–55. [Kolbin A. S., Koroleva O. A., Klimko N. N. Evaluation of the costeffectiveness of voriconazole for treatment of invasive aspergillosis. Farmacoeconomicа. Sovremennaya armakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology 2009;3:46–55. (In Russ.)].11. Maertens J., Raad I., Petrikkos G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39(11):1563–71.Maertens J., Raad I., Petrikkos G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39(11):1563–71.12. Maertens J., Glasmacher A., erbrecht R. et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with nvasive aspergillosis. Cancer 2006;107(12):2888–97.Maertens J., Glasmacher A., erbrecht R. et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with nvasive aspergillosis. Cancer 2006;107(12):2888–97.13. Walsh T. J., Hiemenz J. W., Seibel N. L. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26(6):1383–96.Walsh T. J., Hiemenz J. W., Seibel N. L. et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26(6):1383–96.14. Walsh T. J., Raad I., Patterson T. F. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2–12.Walsh T. J., Raad I., Patterson T. F. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44(1):2–12.15. Viscoli C., Herbrecht R., Akan H. et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009;64(6):1274–81.Viscoli C., Herbrecht R., Akan H. et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009;64(6):1274–81.16. Chandrasekar P. H., Ito J. I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005;40(Suppl 6):S392–400.Chandrasekar P. H., Ito J. I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005;40(Suppl 6):S392–400.17. Cornely O., Maertens J., Bresnik M. et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289–97.Cornely O., Maertens J., Bresnik M. et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289–97.18. Mills W., Chopra R., Linch D. C., Goldstone A. H. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86(4):754–60.Mills W., Chopra R., Linch D. C., Goldstone A. H. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86(4):754–60.19. Bates D. W., Spell N., Cullen D. J. et al. The costs of adverse drug events in hospitalized patients; Adverse Drug Events Prevention Study Group. JAMA 1997;277(4):307–11.Bates D. W., Spell N., Cullen D. J. et al. The costs of adverse drug events in hospitalized patients; Adverse Drug Events Prevention Study Group. JAMA 1997;277(4):307–11.20. Доклад о реализации Программы государственных гарантий бесплатного оказания гражданам медицинской помощи в 2013 году. http://www.rosminzdrav.ru/ documents/8122-doklad-o-realizatsiiprogrammy-gosudarstvennyh-garantiybesplatnogo- okazaniya-grazhdanammeditsinskoy- pomoschi-v-2013-godu (дата обращения: 08.01.2015). [Report of implementation of state guarantees program of free medical care provision in 2013. http://www.rosminzdrav.ru/ documents/8122-doklad-o- ealizatsiiprogrammy- gosudarstvennyh-garantiybesplatnogo- okazaniya-grazhdanammeditsinskoy- pomoschi-v-2013-godu (the date of handling: 08.01.2015). (In Russ.)].Доклад о реализации Программы государственных гарантий бесплатного оказания гражданам медицинской помощи в 2013 году. http://www.rosminzdrav.ru/ documents/8122-doklad-o-realizatsiiprogrammy-gosudarstvennyh-garantiybesplatnogo- okazaniya-grazhdanammeditsinskoy- pomoschi-v-2013-godu (дата обращения: 08.01.2015). [Report of implementation of state guarantees program of free medical care provision in 2013. http://www.rosminzdrav.ru/ documents/8122-doklad-o- ealizatsiiprogrammy- gosudarstvennyh-garantiybesplatnogo- okazaniya-grazhdanammeditsinskoy- pomoschi-v-2013-godu (the date of handling: 08.01.2015). (In Russ.)].21. Климко Н. Н., Шадривова О. В., Хостелиди С. Н. и др. Инвазивный аспергиллез: результаты многоцентро- вого исследования. Онкогематология 2014;2:13–9. [Klimko N. N., Schadrivova O. V., Khostelidi S. N. et al. Invasive aspergillosis: results of multicenter study. Onkogematologiya = Oncohematology 2014;2:13–9. (In Russ.)].Климко Н. Н., Шадривова О. В., Хостелиди С. Н. и др. Инвазивный аспергиллез: результаты многоцентро- вого исследования. Онкогематология 2014;2:13–9. [Klimko N. N., Schadrivova O. V., Khostelidi S. N. et al. Invasive aspergillosis: results of multicenter study. Onkogematologiya = Oncohematology 2014;2:13–9. (In Russ.)].22. Caro J. J., Briggs A. H., Siebert U., Kuntz K. M.; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices – overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force – 1. Value Health 2012;15(6):796–803.Caro J. J., Briggs A. H., Siebert U., Kuntz K. M.; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices – overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force – 1. Value Health 2012;15(6):796–803.23. Briggs A., Claxton K., Sculpher M. J. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.Briggs A., Claxton K., Sculpher M. J. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.24. Walsh T. J., Teppler H., Donowitz G. R. et al. Caspofungin versus liposomal amphotericin for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391–402.Walsh T. J., Teppler H., Donowitz G. R. et al. Caspofungin versus liposomal amphotericin for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391–402.25. Ostermann H., Solano C., Jarque I. et al. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol Toxicol 2014;15:52.Ostermann H., Solano C., Jarque I. et al. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol Toxicol 2014;15:52.26. Dominguez-Gil A., Martin I., Garcia Vargas M. et al. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Investig 2007;27(3):197–205.Dominguez-Gil A., Martin I., Garcia Vargas M. et al. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain. Clin Drug Investig 2007;27(3):197–205.27. Ament A. J., Hubben M. W., Verweij P. E. et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother 2007;60:385–93.Ament A. J., Hubben M. W., Verweij P. E. et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother 2007;60:385–93.28. Wingard J., Herbrecht R., Mauskopf J. et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007;9:182–8.Wingard J., Herbrecht R., Mauskopf J. et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007;9:182–8.29. Lewis J. S., Boucher H. W., Lubowski T. J. et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacother 2005;25(6):839–46.Lewis J. S., Boucher H. W., Lubowski T. J. et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacother 2005;25(6):839–46.30. Garbino J., Schnetzler G., Roberts C. Invasive aspergillosis: is treatment with “inexpensive” amphotericin B costsaving if “expensive” voriconazole is only used on demand. Swiss Medical Weekly 2006;136(39–40):624–30.Garbino J., Schnetzler G., Roberts C. Invasive aspergillosis: is treatment with “inexpensive” amphotericin B costsaving if “expensive” voriconazole is only used on demand. Swiss Medical Weekly 2006;136(39–40):624–30.31. Greene R. E., Mauskopf J., Roberts C. S. et al. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007;64:2561–8.Greene R. E., Mauskopf J., Roberts C. S. et al. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. Am J Health Syst Pharm 2007;64:2561–8.32. Jansen J. P., Meis J. F., Blijlevens N. M., van , t Wout J. W. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005;21(10):1535–46.Jansen J. P., Meis J. F., Blijlevens N. M., van , t Wout J. W. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005;21(10):1535–46.33. Rotstein C., Laverdiere M., Marciniak A., Ali F. An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can J Infect Dis 2004;15(5):277–84.Rotstein C., Laverdiere M., Marciniak A., Ali F. An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada. Can J Infect Dis 2004;15(5):277–84.34. Wenzel R., Del Favero A., Kibbler C. et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55(3):352–61.Wenzel R., Del Favero A., Kibbler C. et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005;55(3):352–61.35. Jansen J. P., Kern W. V., Cornely O. A. et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9(1):12–23.Jansen J. P., Kern W. V., Cornely O. A. et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006;9(1):12–23.36. Hachem R. Y., Boktour M. R., Hanna H. A. et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008;112(6):1282–7.Hachem R. Y., Boktour M. R., Hanna H. A. et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008;112(6):1282–7.